← FDA DRUG APPROVALS

FDA ANDA · ANDA040295

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

Sponsor: ACTAVIS ELIZABETH

APPLICATION
ANDA040295
TYPE
ANDA
ORIGINAL APPROVAL
2000-12-01
LATEST ACTION
2018-06-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEDiscontinued
HOMATROPINE METHYLBROMIDE 1.5MG, HYDROCODONE BITARTRATE 5MG · TABLET · ORAL

Approval history

2018-06-28Labeling · Supplement 9 · standardAP
2017-01-13Labeling · Supplement 8 · standardAP
2016-12-15Labeling · Supplement 7 · standardAP
2001-10-22Manufacturing (CMC) · Supplement 1AP
2000-12-01OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →